ATE200287T1 - Substrate für beta-lactamase und deren verwendung - Google Patents

Substrate für beta-lactamase und deren verwendung

Info

Publication number
ATE200287T1
ATE200287T1 AT96912454T AT96912454T ATE200287T1 AT E200287 T1 ATE200287 T1 AT E200287T1 AT 96912454 T AT96912454 T AT 96912454T AT 96912454 T AT96912454 T AT 96912454T AT E200287 T1 ATE200287 T1 AT E200287T1
Authority
AT
Austria
Prior art keywords
beta
group
lactamase
substrates
chr
Prior art date
Application number
AT96912454T
Other languages
English (en)
Inventor
Roger Y Tsien
Gregor Zlokarnik
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE200287T1 publication Critical patent/ATE200287T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36—Methylene radicals, substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C12P17/184—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system containing a beta-lactam ring, e.g. thienamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/986—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides (3.5.2), e.g. beta-lactamase (penicillinase, 3.5.2.6), creatinine amidohydrolase (creatininase, EC 3.5.2.10), N-methylhydantoinase (3.5.2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2415/00—Assays, e.g. immunoassays or enzyme assays, involving penicillins or cephalosporins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/805—Test papers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT96912454T 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung ATE200287T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/407,544 US5741657A (en) 1995-03-20 1995-03-20 Fluorogenic substrates for β-lactamase and methods of use
PCT/US1996/004059 WO1996030540A2 (en) 1995-03-20 1996-03-20 Substrates for beta-lactamase and uses thereof

Publications (1)

Publication Number Publication Date
ATE200287T1 true ATE200287T1 (de) 2001-04-15

Family

ID=23612529

Family Applications (3)

Application Number Title Priority Date Filing Date
AT99118473T ATE253632T1 (de) 1995-03-20 1996-03-20 Nukleinsäuren und deren verwendung zur bestimmung von beta-laktamase
AT03025361T ATE521715T1 (de) 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung
AT96912454T ATE200287T1 (de) 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT99118473T ATE253632T1 (de) 1995-03-20 1996-03-20 Nukleinsäuren und deren verwendung zur bestimmung von beta-laktamase
AT03025361T ATE521715T1 (de) 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung

Country Status (13)

Country Link
US (5) US5741657A (de)
EP (3) EP1405922B1 (de)
JP (2) JP3633940B2 (de)
CN (2) CN1066731C (de)
AT (3) ATE253632T1 (de)
AU (1) AU723164B2 (de)
CA (1) CA2215310C (de)
DE (2) DE69630622T2 (de)
DK (2) DK0982398T3 (de)
ES (2) ES2156994T3 (de)
MX (1) MX9707213A (de)
PT (1) PT982398E (de)
WO (1) WO1996030540A2 (de)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821727B1 (en) 1993-11-15 2004-11-23 Applera Corporation Hybridization assay using self-quenching fluorescence probe
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US20070020715A1 (en) * 1995-03-20 2007-01-25 The Regents Of The University Of California Novel fluorogenic substrates for beta-lactamase gene expression
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US7427680B2 (en) * 2001-01-12 2008-09-23 The Regents Of The University Of California Fluorogenic substrates for BETA-lactamase gene expression
US20040157262A1 (en) * 1996-04-30 2004-08-12 Michel Kohl Conjugates of haptens to beta-lactam derivatives and their use for detecting and/or quantifying haptens in solution and device for implementation thereof
US7825237B2 (en) * 1996-05-03 2010-11-02 Applied Biosystems, Llc Oligonucleotides and analogs labeled with energy transfer dyes
US7388092B2 (en) * 1996-05-03 2008-06-17 Applera Corporation Oligonucleotides and analogs labeled with energy transfer dyes
US5800996A (en) * 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5945526A (en) * 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US6593135B2 (en) * 1996-08-16 2003-07-15 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Long wavelength engineered fluorescent proteins
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
FI963989L (fi) * 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
US5955604A (en) * 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
CN1254383A (zh) * 1997-05-01 2000-05-24 美国3M公司 基于染料二聚作用的生荧光蛋白水解酶底物
US6214563B1 (en) * 1997-08-01 2001-04-10 Aurora Biosciences Corporation Photon reducing agents for reducing undesired light emission in assays
US6200762B1 (en) * 1997-08-01 2001-03-13 Aurora Biosciences Corporation Photon reducing agents and compositions for fluorescence assays
US6221612B1 (en) * 1997-08-01 2001-04-24 Aurora Biosciences Corporation Photon reducing agents for use in fluorescence assays
US6689574B1 (en) 1997-10-07 2004-02-10 Merck & Co., Inc. Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer
WO1999040114A1 (en) * 1998-02-05 1999-08-12 Merck & Co., Inc. Novel gabab receptor dna sequences
US6284461B1 (en) 1998-04-28 2001-09-04 Aurora Biosciences Corporation Use of inhibitors in reporter assays
US6031094A (en) * 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
US6051395A (en) * 1998-08-25 2000-04-18 Biometric Imaging, Inc. Method and compound for detecting low levels of microorganisms
US6143492A (en) * 1998-12-14 2000-11-07 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
US6420130B1 (en) 1998-12-14 2002-07-16 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
CA2352631A1 (en) * 1998-12-14 2000-06-22 Life Technologies Corporation Optical molecular sensors for cytochrome p450 activity
US6514687B1 (en) * 1998-12-14 2003-02-04 Vertex Pharmaceuticals (San Diego), Llc Optical molecular sensors for cytochrome P450 activity
US8148110B2 (en) * 1999-03-15 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by β-lactamase reporter fragment complementation
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
AU6045900A (en) * 1999-05-25 2000-12-12 Panorama Research, Inc. Interaction-activated proteins
US6358684B1 (en) 1999-08-27 2002-03-19 Pe Corporation UV excitable fluorescent energy transfer dyes
US6218124B1 (en) 1999-08-27 2001-04-17 Pe Corporation Method for detecting oligonucleotides using UV light source
AU3642701A (en) * 1999-11-05 2001-05-30 Iconix Pharmaceuticals, Inc. Hydrolytic enzyme substrates and assay method
US20040072739A1 (en) * 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US6692965B1 (en) * 1999-11-23 2004-02-17 Chromocell Corporation Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences
CA2397162A1 (en) 2000-01-13 2001-07-19 Kalobios, Inc. Circularly permutated, interaction-activated proteins
WO2001053355A1 (en) 2000-01-24 2001-07-26 The Trustees Of Columbia University In The City Of New York An in vivo screen using chemical inducers of dimerization
US7262005B1 (en) * 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
US7029868B2 (en) * 2000-02-17 2006-04-18 Merck & Co., Inc. Cell fusion assays using fluorescence resonance energy transfer
ATE439441T1 (de) * 2000-02-23 2009-08-15 Life Technologies Corp Veränderte, fluoreszierende proteine
EP1143017A3 (de) * 2000-04-03 2004-01-28 Warner-Lambert Company LLC Methoden und Zusammensetzungen zum Screenen von icrac Modulatoren
EP1143013A1 (de) * 2000-04-03 2001-10-10 Warner-Lambert Company Verfahren und Zusammenzetzungen zur Screening von ICRAC-Modulatoren
US6806289B1 (en) 2000-07-14 2004-10-19 Stephen J. Lippard Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
AU2002251755C1 (en) * 2001-01-12 2008-07-10 The Regents Of The University Of California Beta-lactamase substrates having phenolic ethers
US7142306B2 (en) * 2001-01-23 2006-11-28 Schlumberger Technology Corporation Optical probes and probe systems for monitoring fluid flow in a well
US6850317B2 (en) * 2001-01-23 2005-02-01 Schlumberger Technology Corporation Apparatus and methods for determining velocity of oil in a flow stream
US7005511B2 (en) 2001-02-26 2006-02-28 The Regents Of The University Of California Fluorescent protein variants and methods for making same
EP1368058A4 (de) * 2001-03-02 2005-01-12 Merck & Co Inc Virale reporter-partikel
EP1425065A4 (de) * 2001-07-12 2004-12-15 Merck & Co Inc Elektrische feldstimulation mit eukaryontischen zellen
US20030104604A1 (en) * 2001-08-03 2003-06-05 Weiping Yang Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
ES2367539T3 (es) * 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (de) * 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulatoren von lxr
US20050181464A1 (en) * 2002-04-04 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
ES2197811B2 (es) * 2002-04-05 2005-05-01 Universidad Complutense De Madrid Sintesis de derivados fluorescentes de antiobioticos beta-lactamicos.
WO2003089672A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
WO2004003509A2 (en) * 2002-06-28 2004-01-08 Genepharm, Inc. A method to identify specific interaction between ligand and receptor
JP2005532829A (ja) * 2002-07-18 2005-11-04 インヴィトロジェン コーポレーション 組換え部位を含むウイルスベクター
ES2324031T3 (es) * 2002-10-29 2009-07-29 Showa Yakuhin Kako Co., Ltd Composicion de reactivos para discriminar beta-lactamasas, kit y metodo asociados.
ATE455185T1 (de) 2002-11-01 2010-01-15 Univ New York State Res Found Atypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
EP1613160A4 (de) 2003-03-27 2008-01-02 Ptc Therapeutics Inc Betrachtung von enzymen des trna-splice-wegs zur identifikation von antifungalen und/oder proliferationshemmenden molekülen
EP2319318A3 (de) 2003-03-27 2011-08-17 PTC Therapeutics, Inc. Verfahren zur Identifizierung von Verbindungen mit tRNA-Splicing Endonuklease als Aufhänger, und Verwendungen für diese Verbindungen als anti-Proliferationsmittel
US7323303B2 (en) * 2003-03-31 2008-01-29 Hong Kong Polytechnic University Modified β-lactamases and uses thereof
US7473548B2 (en) 2003-04-25 2009-01-06 Medtronic, Inc. Optical detector for enzyme activation
JP4391523B2 (ja) 2003-04-30 2009-12-24 オーロラ ディスカバリー インコーポレイティッド 高密度保存およびアッセイプラットフォームを提供するマルチウェルプレート
US7399639B2 (en) * 2003-05-04 2008-07-15 Massachusetts Institute Of Technology Sensors, and methods of making and using the same
GB0311948D0 (en) * 2003-05-23 2003-06-25 Stockport Innovation Ltd Light emitting probes
WO2005028615A2 (en) * 2003-06-26 2005-03-31 Invitrogen Corporation Methods and compositions for detecting promoter activity and expressing fusion proteins
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
WO2005014796A2 (en) 2003-08-08 2005-02-17 Invitrogen Corporation Methods and compositions for seamless cloning of nucleic acid molecules
US7304168B2 (en) * 2003-08-14 2007-12-04 Board Of Regents, University Of Texas System Photo-caged fluorescent molecules
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
WO2005059167A1 (en) * 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for identifying histone deacetylase inhibitors
WO2005071096A2 (en) * 2004-01-21 2005-08-04 Molecular Probes, Inc. Derivatives of cephalosporin and clavulanic acid for detecting beta-lacamase in a sample
EP2806035B1 (de) * 2004-02-18 2017-09-13 Chromocell Corporation Verfahren und Materialien, die Signalsonden verwenden
KR100663038B1 (ko) 2004-07-22 2007-01-02 학교법인 명지학원 외부유전자의 발현 및 단백질의 분비를 위한 벡터 ｐＭＳＧ1220
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
FR2889700B1 (fr) * 2005-08-11 2012-11-23 Synthinnove Lab Marqueurs, leur procede de fabrication et leurs applications
DE102005044071A1 (de) * 2005-09-07 2007-03-08 Nimbus Biotechnologie Gmbh Verfahren zur Messung der Permeation einer Substanz durch eine Barriere
WO2007100392A2 (en) 2005-11-30 2007-09-07 Biotium, Inc. Enzyme substrate comprising a functional dye and associated technology and methods
CN100487435C (zh) * 2005-12-22 2009-05-13 云南农业大学 一种松树萎蔫病病原线虫的检测方法
US20070218456A1 (en) * 2006-02-08 2007-09-20 Invitrogen Corporation Cellular assays for signaling receptors
US20090075378A1 (en) * 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
US20110065595A1 (en) * 2007-04-12 2011-03-17 Nathan Citri Method and Test Kit for the Rapid Identification and Characterization of Cells
US8097434B2 (en) * 2007-10-19 2012-01-17 Becton, Dickinson And Company Methods for the detection of beta-lactamases
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
US7867758B2 (en) * 2008-04-01 2011-01-11 The Board Of Trustees Of The Leland Stanford Junior University Bioluminogenic assay system for measuring beta-lactamase activity
ES2699376T3 (es) 2008-05-05 2019-02-11 Massachusetts Gen Hospital Métodos para usar sustratos enzimáticos marcados con bodipy
WO2010016911A2 (en) * 2008-08-06 2010-02-11 The Texas A & M University System Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics
WO2010047778A1 (en) 2008-10-20 2010-04-29 Becton Dickinson And Company Compositions for the detection of intracellular bacterial targets and other intracellular microorganism targets
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
WO2010068747A1 (en) 2008-12-12 2010-06-17 University Of Florida Research Foundation, Inc. Cell-based detection of apf through its interaction with ckap4 for diagnosis of interstitial cystitis
US8431416B2 (en) 2009-04-01 2013-04-30 Becton, Dickinson And Company Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates
EP2414507B1 (de) 2009-04-03 2014-07-02 Medical Research Council Mutanten von aktivierungsinduzierter cytidin-deaminase (aid) und verwendungsverfahren
US8609364B2 (en) 2009-05-07 2013-12-17 bioM{tilde over (e)}rieux, Inc. Methods for antimicrobial resistance determination
US9400273B1 (en) 2009-12-09 2016-07-26 Life Technologies Corporation 7-hydroxycoumarin-based cell-tracking reagents
US8318953B2 (en) * 2010-06-23 2012-11-27 Aat Bioquest, Inc. Reactive coumarin derivatives and their use in cellular analyses
CN102115780B (zh) * 2010-12-15 2013-01-30 黑龙江省乳品工业技术开发中心 一种检测β-内酰胺酶的试剂盒及其制备和检测方法
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2013053953A1 (en) * 2011-10-14 2013-04-18 Université de Liège Method for measuring beta-lactam antibiotics
CN103509083B (zh) * 2012-06-28 2016-06-08 王郁生 一种广谱β-内酰胺酶荧光底物及其制备方法和应用
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
EP3151866B1 (de) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimäre kapside
EP3183580B1 (de) 2014-08-21 2025-03-26 Eurofins DiscoverX Corporation Homogener thermal-shift-ligandenbindungstest
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
MX2017009336A (es) 2015-01-16 2017-11-15 Voyager Therapeutics Inc Polinucleótidos dirigidos al sistema nervioso central.
CN104714006B (zh) * 2015-02-04 2017-10-20 国家纳米科学中心 一种检测奶制品中β‑内酰胺酶的方法
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
EP3384035A4 (de) 2015-12-02 2019-08-07 Voyager Therapeutics, Inc. Assays zum nachweis von aav-neutralisierenden antikörpern
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CN108623617B (zh) * 2017-03-22 2021-04-02 蒋辉 一种头孢噻呋中间体的制备方法
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (de) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur aav-freisetzung
US10739331B2 (en) * 2017-08-11 2020-08-11 Bioventures, Llc OMA1 activity assay
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
EP3697908A1 (de) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
EP3762500A1 (de) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
CA3097192A1 (en) 2018-04-27 2019-10-31 Voyager Therapeutics, Inc. Methods for measuring the potency of aadc viral vectors
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
WO2019222329A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3856762A1 (de) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin-expressionskonstrukte mit gentechnisch veränderten promotoren und verfahren zu deren verwendung
KR20240033101A (ko) 2019-05-02 2024-03-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 합성 단백질 안정성을 증가시키기 위한 시스템 및 방법
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
JP7713956B2 (ja) 2020-04-15 2025-07-28 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
TWI900553B (zh) 2020-05-13 2025-10-11 美商航海家醫療公司 Aav蛋白殼之趨性重定向
CN111621492B (zh) * 2020-06-15 2021-10-26 安徽红杉生物医药科技有限公司 内酰胺酶及其应用和酶法拆分制备(1r，4s)-文斯内酯的方法
WO2022026410A2 (en) 2020-07-27 2022-02-03 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250049955A1 (en) 2021-11-17 2025-02-13 Voyager Therapeutics, Inc. Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2024226761A2 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2024229161A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2024229173A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
KR20260021096A (ko) 2023-05-03 2026-02-12 보이저 테라퓨틱스, 인크. Cdkl5 결핍과 관련된 장애의 치료를 위한 조성물 및 방법
WO2024229164A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
AU2024266519A1 (en) 2023-05-03 2025-12-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
WO2025038802A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025038805A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025038795A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025038796A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025122536A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025122543A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
WO2025122548A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025122532A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025122530A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025137219A1 (en) 2023-12-21 2025-06-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS563876B2 (de) * 1973-06-22 1981-01-27
JPS534810B2 (de) 1975-02-13 1978-02-21
US4234683A (en) * 1978-11-24 1980-11-18 Mcmillan William A Beta-lactamase diagnostic product and method
DE2916433A1 (de) * 1979-04-24 1980-11-13 Hoechst Ag Chromophore cephalosporine und verfahren zu ihrer herstellung
DE3019451A1 (de) * 1980-05-21 1981-11-26 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und reagens zur bestimmung von (beta) -lactamasen
FR2494279A1 (fr) * 1980-11-20 1982-05-21 Rhone Poulenc Ind Nouvelles oxacephalosporines, leur preparation et les medicaments qui les contiennent
US4740459A (en) * 1984-08-06 1988-04-26 Washington Research Foundation Fluorescence assay for microbial beta-lactamase
US4760018A (en) * 1985-06-17 1988-07-26 Penicillin Assays, Inc. Rapid method for the detection of beta-lactamase in body fluids
US4764462A (en) * 1985-08-23 1988-08-16 Georgetown University Detectably labeled cephalosporin assay for beta-lactamase
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
GB8819104D0 (en) * 1988-08-11 1988-09-14 Beecham Group Plc Novel compounds
US4978613A (en) * 1989-01-17 1990-12-18 Abbott Laboratories Beta-lactamase assay employing chromogenic precipitating substrates
JPH04503306A (ja) * 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
EP0517768A1 (de) * 1990-02-28 1992-12-16 Schering Corporation Expressionsvektoren für säugetierzellen
US5264346A (en) * 1991-06-03 1993-11-23 Chen Kirk C S Colorimetric method for beta-lactamase assay and its applications
US5162524B1 (en) * 1991-06-06 1997-06-17 Bristol Myers Squibb Co Processes for making cephems from allenylazetidinone derivatives
US5639596A (en) * 1991-08-16 1997-06-17 Gsf-Forschungszentrum Fur Umweltund Gesundheit DNA construct and in vitro test for detecting tumor promoters by means of said DNA construct
US5356797A (en) * 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
US5338843A (en) * 1992-01-30 1994-08-16 Becton, Dickinson And Company Fluorogenic and chromogenic β-lactamase substrates
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
GB9523703D0 (en) * 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
US5955604A (en) * 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof

Also Published As

Publication number Publication date
CN1213144C (zh) 2005-08-03
EP1405922A2 (de) 2004-04-07
DE69630622D1 (de) 2003-12-11
JP2005021172A (ja) 2005-01-27
ATE521715T1 (de) 2011-09-15
DE69612375D1 (de) 2001-05-10
CA2215310A1 (en) 1996-10-03
ES2156994T3 (es) 2001-08-01
US6472205B1 (en) 2002-10-29
JP3856807B2 (ja) 2006-12-13
WO1996030540A2 (en) 1996-10-03
CN1296078A (zh) 2001-05-23
DK0982398T3 (da) 2004-02-16
EP0982398A1 (de) 2000-03-01
DK0817785T3 (da) 2001-07-02
AU723164B2 (en) 2000-08-17
EP1405922A3 (de) 2004-09-29
PT982398E (pt) 2004-02-27
US20070184513A1 (en) 2007-08-09
EP0817785A2 (de) 1998-01-14
US20030119085A1 (en) 2003-06-26
MX9707213A (es) 1998-07-31
EP1405922B1 (de) 2011-08-24
CN1066731C (zh) 2001-06-06
US7157575B2 (en) 2007-01-02
JPH11502714A (ja) 1999-03-09
AU5526696A (en) 1996-10-16
CN1184479A (zh) 1998-06-10
JP3633940B2 (ja) 2005-03-30
US5741657A (en) 1998-04-21
DE69612375T2 (de) 2001-10-31
ATE253632T1 (de) 2003-11-15
DE69630622T2 (de) 2004-09-23
EP0982398B1 (de) 2003-11-05
EP0817785B1 (de) 2001-04-04
CA2215310C (en) 2002-05-21
ES2209305T3 (es) 2004-06-16
US8071761B2 (en) 2011-12-06
WO1996030540A3 (en) 1997-01-09
US6291162B1 (en) 2001-09-18

Similar Documents

Publication Publication Date Title
ATE200287T1 (de) Substrate für beta-lactamase und deren verwendung
EP0767382A3 (de) Fluoreszierende Verbindungen und deren Verwendung zum Messen von Reticulozyten
HU9502811D0 (en) N-acyl-sulfamic acid esters (or thioesters), n-acyl-sulfonamides and n-sulfonyl-carbamic-acid-esters (or thioesters) as hypercholesterolemic agents
ATE132156T1 (de) Latente carbamat-silizium-haftvermittler und verfahren zu deren herstellung und verwendung
PE43597A1 (es) Procedimiento y derivados de n-(3-benzofuranil)urea
GB9815163D0 (en) Compounds
CA2009925A1 (en) Method for enhancement of chemiluminescence
IE812460L (en) Substituted azabicyclo-octane-carboxylic acids
WO1996031531A3 (en) Fluorescent peptides
AT397654B (de) Neue pleuromutilinderivate, ihre verwendung und verfahren zu ihrer herstellung
DE59010297D1 (de) Verfahren zur spezifischen Bestimmung von Pankreas-alpha-Amylase
WO2006085978A3 (en) Conjugates of a cephalosporin derivative and a fluorophor precursor and related compounds as substrates for beta-lactamase gene expression
ATE171936T1 (de) Salpetersäureester von 2-(2,6-dihalophenylamino) phenylacetoessigsäurederivaten und verfahren zu ihrer herstellung
WO2002068678A3 (en) Beta-lactamase substrates having phenolic ethers
ATE116991T1 (de) Semisynthetische rhodomycine, verfahren zu ihrer herstellung und ihre verwendung als zytostatika.
ES8303434A1 (es) Procedimiento para la obtencion de amidas del ester de acido fosforico (fosfonico).
PT98699A (pt) Processo de acidos acilaminometanofosfonicos e de acidos acilaminometil-fosfinicos
ATE84780T1 (de) Neue di(meth)acrylate, verfahren zu deren herstellung und deren verwendung.
EP0802194A3 (de) Thioürazil-Derivate und diese enthaltende Metall-Oberflächebehandlungsmittel
IE812876L (en) Ethers of substituted hydroxymethylpyrazines
AU553351B2 (en) Organophosphate derivatives
DE59300004D1 (de) 2,3-Dihydroxychinoxalinverbindungen.
ATE80882T1 (de) (ethylenedioxo-3,3 zyclohexyl)-4 aketophenon und derivate davon, verfahren zu deren herstellung und verwendung dieser verbindungen.